Supriya Lifescience Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a significant surge in its profit after tax, which grew by 196% year-on-year to ₹240.43 crore. Revenue also saw a substantial increase, reflecting strong operational performance and market demand for its products during the period.
Strong Financial Performance for Q1 FY27
Supriya Lifescience Limited has released its unaudited financial results for the first quarter of the financial year 2026-27, ending June 30, 2026. The company has demonstrated robust financial performance, with its Profit After Tax witnessing a substantial 196% increase to ₹240.43 crore for the quarter. This marks a significant improvement from the corresponding period in the previous year.
Revenue and Comprehensive Income Growth
The company’s total income for the quarter amounted to ₹1,923.95 crore. This revenue figure, coupled with effective cost management, has contributed to the impressive profit growth. The Total Comprehensive Income for the period also saw a significant rise, reaching ₹246.90 crore. These results indicate a strong upward trajectory for Supriya Lifescience in the current fiscal year.
Earnings Per Share
Reflecting the enhanced profitability, the Earnings Per Share (EPS) for the quarter ended June 30, 2026, stood at ₹2.99 for both basic and diluted calculations. This strong EPS performance is a key indicator of the value being generated for shareholders.
Operational Highlights
The financial results were approved by the Board of Directors on August 13, 2026. The company also noted that a material dispatch for export was intercepted and detained by customs, with the goods remaining in customs custody as of June 30, 2026. However, the transaction has been recognized as a sale, as the shipment had already reached customs for processing.
Source: BSE
